Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT06072781IIIRecurrent low grade serous ovarian cancerA Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)AZ, CT, FL, IL, MI, MN, MO, OK, OR, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT03428802IIAdvanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIPlatinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive high grade serous ovarian cancer with BRCA1/2 mutations or HRD+ w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03579316IIPlatinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitorEFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03682289IIAdvanced solid tumors with ARID1A or ATM alterationsPhase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®OK, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
StenoparibPARP/Tankyrase inhibitor 2X-121, E7449, 2X-121PARP inhibitorClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineCAPE, XelodaRNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02710253IIAdvanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyIrradiation, Radiotherapy
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AZ, AR, CA, CO, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AdagrasibKRAS G12C inhibitor MRTX849, MRTX849KRAS G12C inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
PaxalisibGDC-0084, PI3K inhibitor GDC-0084, RG7666PI3K/mTOR inhibitorClinical Trials
NCT04387227IIRecurrent ovarian cancer (only detectable by rising CA125)A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04449549IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04469764IIRecurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterationsAn Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT04550494IIAdvanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor)A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseFL, MD, OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3MI, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04589845IIAdvanced solid tumors with alterations in ALK, ATM, BRAF (class III), KRAS G12C, NTRK1/2/3, PIK3CA (multiple mutations), RET, ROS1 or SETD2Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialAZ, CA, CO, FL, GA, ID, MD, MI, MN, MT, NE, NH, NJ, NM, NY, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
BelvarafenibHM95573BRAF kinase inhibitorClinical Trials
CamonsertibRP-3500ATR kinase inhibitorClinical Trials
DivarasibGDC-6036KRAS G12C inhibitorClinical Trials
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
PralsetinibBLU-667RET-kinase inhibitorApproved in Other Cancers
NCT04771520IIAdvanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvapritinibPDGFRa and c-Kit inhibitorApproved in Other Cancers
NCT02896335IIPatients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2AA Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK PathwayMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PegcetacoplanC3-targeted complement inhibitor APL-2, APL-2Blocks the cleavage of C3Approved in Other Indications
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04957615IIAdvanced solid tumors with ARID1A mutationsA Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05064280IIAdvanced solid tumors with brain metastasesPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05071937IIRecurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens)Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05097599IIAdvanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid TumorsCA, DE, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AxitinibInlyta, AG-013736Multi-targeted RTK inhibitor
BinimetinibMEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, MektoviMEK inhibitorApproved in Other Cancers
EncorafenibRaf Kinase Inhibitor LGX818, LGX818RAF inhibitorApproved in Other Cancers
Enfortumab VedotinADC: anti-Nectin-4 + microtubule destabilizer (MMAE)Approved in Other Cancers
LorlatinibPF-06463922ALK and ROS1 kinase inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Sacituzumab govitecanTrodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)Approved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Ovarian Cancer
NCT05113368IIRecurrect low grade serous ovarian cancerEfficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm TrialOHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FulvestrantZD9238, ICI 182,780, FaslodexER antagonist (SERD)Approved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
NCT05185947IIRecurrent or persistent ovarian cancer with peritoneal disease (IP/IV)Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04992013IIOvarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNSMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05231122IIRecurrent serous, endometrioid or clear cell ovarian cancerRandomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerNY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CDX-1140Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05286801IIAdvanced solid tumors with loss of SMARCB1 or SMARCA1A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsAL, CA, CO, DC, GA, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, OR, PA, TN, TX, UT, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT05296512IIRecurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell componentA Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the OvaryIL, MA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05327010IIAdvanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with prior PARP inhibitor therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitorPhase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)CA, CO, FL, GA, IL, KY, MD, NC, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05337735IIAdvanced solid tumors with dMMR or high MSIA Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VudalimabXmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
NCT05489211IIAdvanced solid tumorsA Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid TumoursCA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
SaruparibAZD5305PARP1 inhibitorClinical Trials
NCT05512208IIRecurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)NM, OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT05523440IIRecurrent ovarian cancer with ARID1A mutationsPhase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)OKView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05554367IIAdvanced solid tumors with alterations in BRAF, HRAS, KRAS, NRAS or RAF, or low grade serous ovarian cancer with progression on prior MEK inhibitorPalbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment TrialAL, ID, IL, IA, ME, MI, MN, MO, MT, NM, NY, ND, OH, OK, OR, PA, SC, SD, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BinimetinibMEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, MektoviMEK inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT05503797IIAdvanced solid cancers with a BRAF fusionA Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF AlterationsCA, FL, MD, MA, MN, MO, NE, NJ, NY, OH, RI, TX, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Plixorafenib8394, BRAF inhibitor PLX8394, FORE8394BRAF kinase inhibitorClinical Trials
NCT05147558IIRecurrent carcinosarcomaA Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian CarcinosarcomasNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05634785IIAdvanced CD30+ nonseminomatous germ cell tumorsAdministration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)NCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ATLCAR.CD30autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytesImmune response against cancer expressing CD30Clinical Trials
NCT05638295IIAdvanced solid tumors with a KRAS G12C mutationA Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment TrialID, IL, IA, ME, MI, MO, MT, OK, OR, PA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PanitumumabVectibix, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal AntibodyEGFR antagonist
SotorasibSotorasib, KRAS mutant-targeting AMG 510, AMG 510KRAS G12C inhibitorApproved in Other Cancers
NCT05661578IIAdvanced PD-L1+ solid tumorsA Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsKY, NE, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT05673928IIAdvanced HER2+ solid tumors with brain metastasesA Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT05700721IIAdvanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54LPhase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05798611IIAdvanced solid tumors with dMMR or high MSIA Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)CA, IL, MA, NY, OK, PA, RIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ART0380ATR kinase inhibitorClinical Trials
NCT05983276IIRecurrent ovarian cancerCombination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian CancerILView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Decitabinedezocitidine, deoxyazacytidine, 5-aza-dCyd, DacogenDNA methylation inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
Selinexorselective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, XpovioSelective inhibition of nuclear export (SINE)Approved in Other Cancers
NCT06126276IIAdvanced solid tumors with ERBB2 AMPA Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialID, IL, IA, ME, MI, MO, MT, OH, TX, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT06169124IIRecurrent granulosa cell tumor with progression on prior aromatase inhibitorA Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination With Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell TumorCA, DE, ID, IL, IN, IA, ME, MI, MO, MT, NE, NC, OH, OK, OR, PA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DarolutamideNubeqaAR antagonistApproved in Other Cancers
ExemestaneAromasinAromatase inhibitorApproved in Other Cancers
Leuprolide acetateLupronGnRH agonistApproved in Other Cancers
NCT05787561IIRecurrent or persistent mesonephric or mesonephric-like gynecologic cancer; no prior FAK, RAF or MEK inhibitorSingle Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT05032040IIPlatinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens)A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate CancerCA, FL, GA, MI, NV, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VudalimabXmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
NCT05405595Ib/IIAdvanced solid tumors (Phase II)A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid TumorsAZ, CA, FLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ADG126anti-CTLA-4 SAFEbody ADG126, anti-CTLA-4 monoclonal antibody ADG126Blocks CTLA-4 inhibition of T cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05700669Ib/IIRecurrent ovarian cancerA Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AsiDNADNA repair inhibiting oligonucleotideDNA Repair decoyClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03872947IbRecurrent ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, NY, OR, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT04130516I/IIaAdvanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II)A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without PembrolizumabCA, CT, MA, NM, NY, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LNS8801G protein-coupled estrogen receptor agonist LNS8801GPER agonistClinical Trials
NCT05123482I/IIaRecurrent B7H4+ ovarian cancerA Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid MalignanciesCA, MD, MA, MO, NM, NY, NC, PA, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD8205ADC: anti-B7H4 + topoisomerase I inhibitor (AZ14170132)Clinical Trials
NCT02484404I/IIRecurrent ovarian cancer (Phase II)Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03157128I/IIAdvanced solid tumors with RET alterations (Phase II)A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibLOXO-292, RET kinase inhibitor LOXO-292, RetevmoRET-kinase inhibitorApproved in Other Cancers
NCT03767348I/IIAdvanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT03093116I/IIAdvanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RepotrectinibTPX-0005, ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitorApproved in Other Cancers
NCT03175224I/IIAdvanced solid tumors with MET amplifications or MET gene fusions (Phase II)Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsCA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VebreltinibCBT-101, APL-101, Bozitinibc-Met kinase inhibitorClinical Trials
NCT04561362I/IIAdvanced solid tumors (Phase II)Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced MalignanciesCO, FL, NY, OH, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BT8009BT8009 - a Nectin-4-targeting Bicycle Toxin Conjugate, BT8009-100ADC: anti-Nectin-4 + microtubule destabilizer (MMAE)Clinical Trials
NCT04590326I/IIRecurrent ovarian cancerPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)CA, FL, IL, MA, MI, NY, OH, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, REGN2810, LibtayoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
REGN5668Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cellsClinical Trials
UbamatamabREGN4018, anti-MUC16/CD3 bispecific antibody REGN4018Re-directs T cells to attack MUC16 (CA125)+ tumor cellsClinical Trials
NCT04243499I/IIRecurrent ovarian cancer with high levels of γ9δ2 T cellsA First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory CancerCT, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ICT01Activates gamma/delta T cells to stimulate immune responseClinical Trials
NCT04956640I/IIAdvanced solid tumors with a KRAS G12C mutation (Phase II)A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid TumorsAL, CA, CT, FL, IN, MA, NH, NY, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LY3537982KRAS G12C inhibitorClinical Trials
NCT05001282I/IIRecurrent FRalpha+ ovarian cancerDose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing TumorsCA, FL, IL, MN, NY, NC, OH, PA, RI, SD, TN, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ELU001ADC: Folic Acid analogs + topoisomerase I inhibitor (exatecan)Clinical Trials
NCT05118789I/IIAdvanced solid tumors with ROS1 rearrangement (Phase II)A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)CA, CO, DC, FL, MA, MI, MO, NY, NC, PA, TN, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NVL-520ROS1 kinase inhibitorClinical Trials
NCT05262530I/IIRecurrent CLDN6+ ovarian cancerFirst-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid TumorsIN, MD, NY, NC, PA, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BNT142BNT142 RiboMab (mRNA-encoded antibody)Re-directs T cells to attack CLDN6+ tumor cellsClinical Trials
NCT03190941I/IIAdvanced solid tumors with a RAS G12V mutationA Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Anti-KRAS G12V mTCR PBLImmune response against cancer expressing RAS G12VClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT05920798I/IIRecurrent ovarian cancer; all lesions must be less than 5 cmFRαDCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian CancerMNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FRalpha DC vaccineMulti-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, FRalphaDCsImmune response against cancer expressing folate receptorClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT06065059I/IIAdvanced solid BRCA MUT or HRD+ tumors (inc ovarian expansion)Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid TumorsCO, FL, MA, NY, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
TNG348USP1 inhibitorClinical Trials
NCT06065462I/IIRecurrent clear cell ovarian cancer without a PPP2R1A mutationSafety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
LB-100protein phosphatase 2A inhibitor LB-100PP2A inhibitorClinical Trials
NCT05579366I/IIRecurrent ovarian cancer (Phase II)Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid TumorsCA, KS, MA, MI, OK, TN, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Rinatabart sesutecanPRO1184ADC: anti-FRalpha + topoisomerase I inhibitor (exatecan)Clinical Trials
NCT02264678IPlatinum sensitive ovarian cancer with BRCA1/2, PALB2 or RAD51C/D mutations, or HRD+ that must have progressed on PARP inhibitor, no prior ATR inhibitorA Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.CA, MA, NY, NC, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
SaruparibAZD5305PARP1 inhibitorClinical Trials
NCT03821935IRecurrent Granulosa Cell Tumors (no prior PD-1 inhibitor therapy)A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid TumorsCT, FL, IN, MO, NY, OH, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BudigalimabABBV-181, anti-PD1 monoclonal antibody ABBV-181Blocks PD-L1/2 inhibition of T cellsClinical Trials
Livmoniplimabanti-GARP monoclonal antibody ABBV-151, ARGX-115, ABBV-151Binds GARP in complex with inactive TGF-beta preventing release of active TGF-betaClinical Trials
NCT03905148IAdvanced solid tumors with NRAS alterations (in expansion)A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid TumorsCA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LifirafenibBRAF/EGFR inhibitor BGB-283, BGB-283, LifirfenibBRAF and EGFR inhibitorClinical Trials
MirdametinibMEK inhibitor PD0325901, PD-0325901MEK inhibitorClinical Trials
NCT03968406IRecurrent ovarian cancer (amenable to radiation therapy) - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyIrradiation, Radiotherapy
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04053673IAdvanced solid tumors with TIPARP amplification (in expansion)A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsCO, CT, FL, MA, MO, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RBN-2397PARP7 inhibitorClinical Trials
NCT04092270IRecurrent ovarian cancer (inc expansion)A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)CO, GA, MA, NJ, NY, OH, OK, PA, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
NCT04249843IAdvanced solid tumors with BRAF mutations Class II: K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, G469S or BRAF fusion or BRAF V600 tumors with progression after prior BRAF inhibitor or MEK inhibitor (in expansion)A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory TumorsCA, LA, MA, NY, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrimarafenibBGB-3245BRAF kinase inhibitorClinical Trials
NCT04315233IRecurrent serous ovarian cancerA Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT04329494IRecurrent ovarian cancer with peritoneal diseaseSafety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)CA, FL, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
PIPACpressurized intraperitoneal aerosol chemotherapyClinical Trials
NCT03809624IAdvanced solid tumors with PD-L1 CPS ≥ 5 (in expansion)An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid TumorsAZ, CA, GA, IN, KY, MA, MI, MO, NE, OR, PA, TN, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INBRX-105anti-PD-L1/4-1BB bispecific antibody INBRX-105Stimulates 4-1BB (CD137) to increase T cell activation and immune response and blocks PD-L1 inhibition of T cellsClinical Trials
NCT04673448IRecurrent ovarian cancer with BRCA1/2 mutationsPhase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT04703920IRecurrent high grade serous ovarian cancerA Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerMIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04707248IRecurrent ovarian cancer (in expansion)Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsAZ, CO, FL, OK, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Raludotatug deruxtecanDS-6000aADC: anti-CDH6 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT04890613IOvarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutationsPhase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 MutationCA, FL, MA, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PidnarulexPol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461Pol I inhibitorClinical Trials
NCT05057715IPersistent or recurrent serous ovarian cancerPhase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
VCN-01PH20 hyaluronidase-expressing adenovirus VCN-01Induces immune response and tumor cell lysisClinical Trials
NCT05103683IAdvanced solid tumors (in ovarian expansion)A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced CancerCA, MN, OHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TORL-1-23ADC: anti-CLDN6 + microtubule destabilizer (MMAE)Clinical Trials
NCT05109975IRecurrent high grade ovarian cancer with CCNE1 AMPA Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor ActivityMI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Debio 0123WEE1 inhibitorClinical Trials
NCT05156866IAdvanced solid tumors (in expansion)A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced CancerCA, INView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TORL-2-307-ADCADC: anti-CLDN18.2 + microtubule destabilizer (MMAE)Clinical Trials
NCT05159440IAdvanced solid tumors (in expansion)A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced CancerCA, INView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TORL-2-307-MABAnti-tumor immune responseClinical Trials
NCT05216432IAdvanced solid tumors (inc ovarian expansion)A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast CancerAZ, CO, FL, IL, MA, MI, NY, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RLY-2608PI3K alpha inhibitorClinical Trials
NCT05238922IAdvanced solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid TumorsCA, CO, GA, NY, PA, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INCB123667CDK2 inhibitorClinical Trials
NCT05271318IRecurrent ovarian cancerA Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Platinum Resistant or Refractory Ovarian CancerMN, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Igrelimogene litadenorepvecTNFalpha/IL-2-encoding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123Induces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05346484IAdvanced solid tumors - optional intratumoral injection (in expansion)A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).AZ, AR, CA, FL, MI, OH, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CF33-hNISCF33-hNIS (hNIS - human sodium iodide symporter), VAXINIA, HOV2Induces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05417594IRecurrent ovarian cancer with a BRCA1/2, PALB2 or RAD51C/D alteration (monotherapy, at most 1 prior PARP inhibitor therapy) or advanced HER2+ solid tumors (combo w/ trastuzumab deruxtecan) or advanced solid tumors (combo w/ datopotamab deruxtecan)A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)CA, IL, MA, NY, OR, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD9574PARP1 inhibitorClinical Trials
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Ovarian Cancer
NCT05527184IRecurrent high grade serous ovarian cancer (inc expansion)A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersCA, CO, FL, OK, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IMGN151ADC: anti-FRalpha + microtubule destabilizer (DM21)Clinical Trials
NCT03401385IAdvanced solid tumors (in expansion)Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)CA, DC, GA, MD, MA, NY, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT03745326IAdvanced solid tumors with a RAS G12D mutationA Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Anti-KRAS G12D mTCR PBLImmune response against cancer expressing RAS G12DClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT05787587IRecurrent HRD+ ovarian cancer and advanced solid tumors with alterations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCA/L, NBN, PALB2, PPP2R2A, RAD51B/C/D, RAD54L or high LOH or HRD+ (in ovarian expansion)A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsAZ, CA, CO, CT, GA, IN, MA, MI, NV, NY, OK, PA, TN, TX, UT, VA, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DarovasertibIDE161PARG inhibitorClinical Trials
NCT05942300IPlatinum sensitive ovarian cancerPhase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
TulmimetostatCPI-0209, EZH2 inhibitor CPI-0209EZH2 histone methyltransferase inhibitorClinical Trials
NCT05950464IRecurrent clear cell or endometrioid ovarian cancer or platinum resistant high grade serous ovarian cancer (inc ovarian expansion)A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerGA, IA, OH, OK, PA, RI, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TuvusertibATR kinase inhibitor M1774, M1774ATR kinase inhibitorClinical Trials
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05989724IAdvanced solid tumors (inc ovarian expansion)A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid TumorsAZ, MI, NC, OK, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SON-DPUndisclosed mechanismClinical Trials
NCT04847063INewly diagnosed or recurrent ovarian cancer with peritoneal diseaseIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials
NCT05039801IAdvanced solid tumors with AKT, KEAP1, NF1, NFE2L2, PIK3CA, PTEN or STK11 (LKB1) alterations, or platinum resistant or refractory high grade serous ovarian cancer with low expression of ASNS, or recurrent clear cell ovarian cancer with an ARID1A mutation or platinum resistant high grade ovarian cancer (combo w/ paclitaxel and bevacizumab) (inc expansion)A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CapivasertibAZD5363, Akt inhibitor AZD5363pan-AKT inhibitorApproved in Other Cancers
IACS-6274glutaminase inhibitor IPN60090, IPN60090Glutaminase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.